鞘氨醇激酶：一个有前景的癌症治疗靶点。 - Suppr

Suppr

超能文献

Sphingosine kinase: a promising cancer therapeutic target.

作者信息

Antoon James W, Beckman Barbara S

机构信息

Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, USA.

出版信息

Cancer Biol Ther. 2011 Apr 1;11(7):647-50. doi: 10.4161/cbt.11.7.14921.

DOI:10.4161/cbt.11.7.14921

PMID:21307640

Abstract

摘要

相似文献

Sphingosine kinase: a promising cancer therapeutic target.

Cancer Biol Ther. 2011 Apr 1;11(7):647-50. doi: 10.4161/cbt.11.7.14921.

Sphingosine kinase 1 as an anticancer therapeutic target.

Drug Des Devel Ther. 2015 Jun 23;9:3239-45. doi: 10.2147/DDDT.S83288. eCollection 2015.

Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy.

Exp Cell Res. 2015 May 1;333(2):195-200. doi: 10.1016/j.yexcr.2015.02.025. Epub 2015 Mar 11.

New perspectives on the role of sphingosine 1-phosphate in cancer.

Handb Exp Pharmacol. 2013(216):55-71. doi: 10.1007/978-3-7091-1511-4_3.

Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.

Handb Exp Pharmacol. 2013(216):3-27. doi: 10.1007/978-3-7091-1511-4_1.

Targeting Sphingosine Kinases for the Treatment of Cancer.

Adv Cancer Res. 2018;140:295-325. doi: 10.1016/bs.acr.2018.04.015. Epub 2018 Jun 9.

Targeting sphingosine kinase 1 in cancer.

Adv Biol Regul. 2012 Jan;52(1):31-8. doi: 10.1016/j.advenzreg.2011.07.001.

Downregulating sphingosine kinase-1 for cancer therapy.

Expert Opin Ther Targets. 2008 Aug;12(8):1009-20. doi: 10.1517/14728222.12.8.1009.

Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.

Curr Pharm Des. 2006;12(35):4625-35. doi: 10.2174/138161206779010422.

Sphingolipids and response to chemotherapy.

Handb Exp Pharmacol. 2013(216):73-91. doi: 10.1007/978-3-7091-1511-4_4.

引用本文的文献

The Role of Sphingolipids Metabolism in Cancer Drug Resistance.

Front Oncol. 2021 Dec 23;11:807636. doi: 10.3389/fonc.2021.807636. eCollection 2021.

Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases.

Liver Res. 2019 Mar;3(1):19-24. doi: 10.1016/j.livres.2019.02.003. Epub 2019 Mar 4.

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.

Eur J Med Chem. 2017 Oct 20;139:461-481. doi: 10.1016/j.ejmech.2017.08.017. Epub 2017 Aug 10.

Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.

Cell Signal. 2017 Apr;32:85-92. doi: 10.1016/j.cellsig.2017.01.021. Epub 2017 Jan 17.

Sphingosine kinase 1 isoform-specific interactions in breast cancer.

Mol Endocrinol. 2014 Nov;28(11):1899-915. doi: 10.1210/me.2013-1423. Epub 2014 Sep 12.

Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Exp Biol Med (Maywood). 2012 Jul;237(7):832-44. doi: 10.1258/ebm.2012.012028. Epub 2012 Aug 2.

Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.

Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Oncol Rep. 2012 Jun;27(6):1779-86. doi: 10.3892/or.2012.1743. Epub 2012 Mar 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Sphingosine kinase: a promising cancer therapeutic target.

Cancer Biol Ther. 2011 Apr 1;11(7):647-50. doi: 10.4161/cbt.11.7.14921.

Sphingosine kinase 1 as an anticancer therapeutic target.

Drug Des Devel Ther. 2015 Jun 23;9:3239-45. doi: 10.2147/DDDT.S83288. eCollection 2015.

Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy.

Exp Cell Res. 2015 May 1;333(2):195-200. doi: 10.1016/j.yexcr.2015.02.025. Epub 2015 Mar 11.

New perspectives on the role of sphingosine 1-phosphate in cancer.

Handb Exp Pharmacol. 2013(216):55-71. doi: 10.1007/978-3-7091-1511-4_3.

Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.

Handb Exp Pharmacol. 2013(216):3-27. doi: 10.1007/978-3-7091-1511-4_1.

Targeting Sphingosine Kinases for the Treatment of Cancer.

Adv Cancer Res. 2018;140:295-325. doi: 10.1016/bs.acr.2018.04.015. Epub 2018 Jun 9.

Targeting sphingosine kinase 1 in cancer.

Adv Biol Regul. 2012 Jan;52(1):31-8. doi: 10.1016/j.advenzreg.2011.07.001.

Downregulating sphingosine kinase-1 for cancer therapy.

Expert Opin Ther Targets. 2008 Aug;12(8):1009-20. doi: 10.1517/14728222.12.8.1009.

Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.

Curr Pharm Des. 2006;12(35):4625-35. doi: 10.2174/138161206779010422.

Sphingolipids and response to chemotherapy.

Handb Exp Pharmacol. 2013(216):73-91. doi: 10.1007/978-3-7091-1511-4_4.

引用本文的文献

The Role of Sphingolipids Metabolism in Cancer Drug Resistance.

Front Oncol. 2021 Dec 23;11:807636. doi: 10.3389/fonc.2021.807636. eCollection 2021.

Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases.

Liver Res. 2019 Mar;3(1):19-24. doi: 10.1016/j.livres.2019.02.003. Epub 2019 Mar 4.

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.

Eur J Med Chem. 2017 Oct 20;139:461-481. doi: 10.1016/j.ejmech.2017.08.017. Epub 2017 Aug 10.

Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.

Cell Signal. 2017 Apr;32:85-92. doi: 10.1016/j.cellsig.2017.01.021. Epub 2017 Jan 17.

Sphingosine kinase 1 isoform-specific interactions in breast cancer.

Mol Endocrinol. 2014 Nov;28(11):1899-915. doi: 10.1210/me.2013-1423. Epub 2014 Sep 12.

Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Exp Biol Med (Maywood). 2012 Jul;237(7):832-44. doi: 10.1258/ebm.2012.012028. Epub 2012 Aug 2.

Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.

Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Oncol Rep. 2012 Jun;27(6):1779-86. doi: 10.3892/or.2012.1743. Epub 2012 Mar 27.